Atropine for the Prevention of Myopia Progression in Children. A Report by the American Academy of Ophthalmology

Stacy L. Pineles, Raymond T. Kraker, Deborah K. VanderVeen, Amy K. Hutchinson, Jennifer A. Galvin, Lorri Wilson, Scott R. Lambert

Research output: Contribution to journalArticle

27 Citations (Scopus)

Abstract

Purpose: To review the published literature on the efficacy of topical atropine for the prevention of myopic progression in children. Methods: Literature searches were last conducted in December 2016 in the PubMed database with no date restrictions, but were limited to studies published in English, and in the Cochrane Library database without any restrictions. The combined searches yielded 98 citations, 23 of which were reviewed in full text. Of these, 17 articles were deemed appropriate for inclusion in this assessment and subsequently were assigned a level of evidence rating by the panel methodologist. Results: Seventeen level I, II, and III studies were identified. Most of the studies reported less myopic progression in children treated with atropine compared with various control groups. All 8 of the level I and II studies that evaluated primarily myopic progression revealed less myopic progression with atropine (myopic progression ranging from 0.04±0.63 to 0.47±0.91 diopters (D)/year) compared with control participants (myopic progression ranging from 0.38±0.39 to 1.19±2.48 D/year). In studies that evaluated myopic progression after cessation of treatment, a rebound effect was noted. Several studies evaluated the optimal dosage of atropine with regard to myopic progression, rebound after treatment cessation, and minimization of side effects. Lower dosages of atropine (0.5%, 0.1%, and 0.01%) were found to be slightly less effective during treatment periods of 1 to 2 years, but they were associated with less rebound myopic progression (for atropine 0.01%, mean myopic progression after treatment cessation of 0.28±0.33 D/year, compared with atropine 0.5%, 0.87±0.52 D/year), fewer side effects, and similar long-term results for myopic progression after the study period and rebound effect were considered. The most robust and well-designed studies were carried out in Asian populations. Studies involving patients of other ethnic backgrounds failed to provide sufficient evidence of an effect of atropine on myopic progression. Conclusions: Level I evidence supports the use of atropine to prevent myopic progression. Although there are reports of myopic rebound after treatment is discontinued, this seems to be minimized by using low doses (especially atropine 0.01%).

Original languageEnglish (US)
JournalOphthalmology
DOIs
StateAccepted/In press - 2017

Fingerprint

Myopia
Atropine
Withholding Treatment
Databases
PubMed
Libraries
Control Groups

ASJC Scopus subject areas

  • Ophthalmology

Cite this

Pineles, S. L., Kraker, R. T., VanderVeen, D. K., Hutchinson, A. K., Galvin, J. A., Wilson, L., & Lambert, S. R. (Accepted/In press). Atropine for the Prevention of Myopia Progression in Children. A Report by the American Academy of Ophthalmology. Ophthalmology. https://doi.org/10.1016/j.ophtha.2017.05.032

Atropine for the Prevention of Myopia Progression in Children. A Report by the American Academy of Ophthalmology. / Pineles, Stacy L.; Kraker, Raymond T.; VanderVeen, Deborah K.; Hutchinson, Amy K.; Galvin, Jennifer A.; Wilson, Lorri; Lambert, Scott R.

In: Ophthalmology, 2017.

Research output: Contribution to journalArticle

Pineles, Stacy L. ; Kraker, Raymond T. ; VanderVeen, Deborah K. ; Hutchinson, Amy K. ; Galvin, Jennifer A. ; Wilson, Lorri ; Lambert, Scott R. / Atropine for the Prevention of Myopia Progression in Children. A Report by the American Academy of Ophthalmology. In: Ophthalmology. 2017.
@article{214f61b8fb784647b67866c90e34886a,
title = "Atropine for the Prevention of Myopia Progression in Children. A Report by the American Academy of Ophthalmology",
abstract = "Purpose: To review the published literature on the efficacy of topical atropine for the prevention of myopic progression in children. Methods: Literature searches were last conducted in December 2016 in the PubMed database with no date restrictions, but were limited to studies published in English, and in the Cochrane Library database without any restrictions. The combined searches yielded 98 citations, 23 of which were reviewed in full text. Of these, 17 articles were deemed appropriate for inclusion in this assessment and subsequently were assigned a level of evidence rating by the panel methodologist. Results: Seventeen level I, II, and III studies were identified. Most of the studies reported less myopic progression in children treated with atropine compared with various control groups. All 8 of the level I and II studies that evaluated primarily myopic progression revealed less myopic progression with atropine (myopic progression ranging from 0.04±0.63 to 0.47±0.91 diopters (D)/year) compared with control participants (myopic progression ranging from 0.38±0.39 to 1.19±2.48 D/year). In studies that evaluated myopic progression after cessation of treatment, a rebound effect was noted. Several studies evaluated the optimal dosage of atropine with regard to myopic progression, rebound after treatment cessation, and minimization of side effects. Lower dosages of atropine (0.5{\%}, 0.1{\%}, and 0.01{\%}) were found to be slightly less effective during treatment periods of 1 to 2 years, but they were associated with less rebound myopic progression (for atropine 0.01{\%}, mean myopic progression after treatment cessation of 0.28±0.33 D/year, compared with atropine 0.5{\%}, 0.87±0.52 D/year), fewer side effects, and similar long-term results for myopic progression after the study period and rebound effect were considered. The most robust and well-designed studies were carried out in Asian populations. Studies involving patients of other ethnic backgrounds failed to provide sufficient evidence of an effect of atropine on myopic progression. Conclusions: Level I evidence supports the use of atropine to prevent myopic progression. Although there are reports of myopic rebound after treatment is discontinued, this seems to be minimized by using low doses (especially atropine 0.01{\%}).",
author = "Pineles, {Stacy L.} and Kraker, {Raymond T.} and VanderVeen, {Deborah K.} and Hutchinson, {Amy K.} and Galvin, {Jennifer A.} and Lorri Wilson and Lambert, {Scott R.}",
year = "2017",
doi = "10.1016/j.ophtha.2017.05.032",
language = "English (US)",
journal = "Ophthalmology",
issn = "0161-6420",
publisher = "Elsevier Inc.",

}

TY - JOUR

T1 - Atropine for the Prevention of Myopia Progression in Children. A Report by the American Academy of Ophthalmology

AU - Pineles, Stacy L.

AU - Kraker, Raymond T.

AU - VanderVeen, Deborah K.

AU - Hutchinson, Amy K.

AU - Galvin, Jennifer A.

AU - Wilson, Lorri

AU - Lambert, Scott R.

PY - 2017

Y1 - 2017

N2 - Purpose: To review the published literature on the efficacy of topical atropine for the prevention of myopic progression in children. Methods: Literature searches were last conducted in December 2016 in the PubMed database with no date restrictions, but were limited to studies published in English, and in the Cochrane Library database without any restrictions. The combined searches yielded 98 citations, 23 of which were reviewed in full text. Of these, 17 articles were deemed appropriate for inclusion in this assessment and subsequently were assigned a level of evidence rating by the panel methodologist. Results: Seventeen level I, II, and III studies were identified. Most of the studies reported less myopic progression in children treated with atropine compared with various control groups. All 8 of the level I and II studies that evaluated primarily myopic progression revealed less myopic progression with atropine (myopic progression ranging from 0.04±0.63 to 0.47±0.91 diopters (D)/year) compared with control participants (myopic progression ranging from 0.38±0.39 to 1.19±2.48 D/year). In studies that evaluated myopic progression after cessation of treatment, a rebound effect was noted. Several studies evaluated the optimal dosage of atropine with regard to myopic progression, rebound after treatment cessation, and minimization of side effects. Lower dosages of atropine (0.5%, 0.1%, and 0.01%) were found to be slightly less effective during treatment periods of 1 to 2 years, but they were associated with less rebound myopic progression (for atropine 0.01%, mean myopic progression after treatment cessation of 0.28±0.33 D/year, compared with atropine 0.5%, 0.87±0.52 D/year), fewer side effects, and similar long-term results for myopic progression after the study period and rebound effect were considered. The most robust and well-designed studies were carried out in Asian populations. Studies involving patients of other ethnic backgrounds failed to provide sufficient evidence of an effect of atropine on myopic progression. Conclusions: Level I evidence supports the use of atropine to prevent myopic progression. Although there are reports of myopic rebound after treatment is discontinued, this seems to be minimized by using low doses (especially atropine 0.01%).

AB - Purpose: To review the published literature on the efficacy of topical atropine for the prevention of myopic progression in children. Methods: Literature searches were last conducted in December 2016 in the PubMed database with no date restrictions, but were limited to studies published in English, and in the Cochrane Library database without any restrictions. The combined searches yielded 98 citations, 23 of which were reviewed in full text. Of these, 17 articles were deemed appropriate for inclusion in this assessment and subsequently were assigned a level of evidence rating by the panel methodologist. Results: Seventeen level I, II, and III studies were identified. Most of the studies reported less myopic progression in children treated with atropine compared with various control groups. All 8 of the level I and II studies that evaluated primarily myopic progression revealed less myopic progression with atropine (myopic progression ranging from 0.04±0.63 to 0.47±0.91 diopters (D)/year) compared with control participants (myopic progression ranging from 0.38±0.39 to 1.19±2.48 D/year). In studies that evaluated myopic progression after cessation of treatment, a rebound effect was noted. Several studies evaluated the optimal dosage of atropine with regard to myopic progression, rebound after treatment cessation, and minimization of side effects. Lower dosages of atropine (0.5%, 0.1%, and 0.01%) were found to be slightly less effective during treatment periods of 1 to 2 years, but they were associated with less rebound myopic progression (for atropine 0.01%, mean myopic progression after treatment cessation of 0.28±0.33 D/year, compared with atropine 0.5%, 0.87±0.52 D/year), fewer side effects, and similar long-term results for myopic progression after the study period and rebound effect were considered. The most robust and well-designed studies were carried out in Asian populations. Studies involving patients of other ethnic backgrounds failed to provide sufficient evidence of an effect of atropine on myopic progression. Conclusions: Level I evidence supports the use of atropine to prevent myopic progression. Although there are reports of myopic rebound after treatment is discontinued, this seems to be minimized by using low doses (especially atropine 0.01%).

UR - http://www.scopus.com/inward/record.url?scp=85021321401&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85021321401&partnerID=8YFLogxK

U2 - 10.1016/j.ophtha.2017.05.032

DO - 10.1016/j.ophtha.2017.05.032

M3 - Article

C2 - 28669492

AN - SCOPUS:85021321401

JO - Ophthalmology

JF - Ophthalmology

SN - 0161-6420

ER -